{"id":"NCT02733367","sponsor":"Neurocrine UK Limited","briefTitle":"Extension Study for Patients Entered Into Study Infacort 003","officialTitle":"Open-label, Long-term Follow-up of Safety and Biochemical Disease Control of Infacort® in Neonates, Infants and Children With Congenital Adrenal Hyperplasia and Adrenal Insufficiency Previously Enrolled in the Infacort 003 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-04","primaryCompletion":"2018-08-10","completion":"2018-08-10","firstPosted":"2016-04-11","resultsPosted":"2019-09-13","lastUpdate":"2019-11-05"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adrenal Insufficiency"],"interventions":[{"type":"DRUG","name":"Infacort®","otherNames":[]}],"arms":[{"label":"Infacort","type":"EXPERIMENTAL"}],"summary":"A Phase 3, open-label, single-group, non-randomised, observational study of the safety and biochemical disease control of Infacort® in neonates, infants and children with adrenal insufficiency and congenital adrenal hyperplasia who had completed study Infacort 003. All subjects who had satisfactorily completed study Infacort 003 were offered the opportunity to take part in Infacort 004.","primaryOutcome":{"measure":"Incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)","timeFrame":"29 months","effectByArm":[{"arm":"Infacort","deltaMin":193,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":18},"commonTop":["Pyrexia","Gastroenteritis","Viral upper respiratory tract infection","Vomiting","Viral infection"]}}